[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508943":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":38,"centralContacts":43,"locations":54,"responsibleParty":67,"collaborators":48,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":48,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":48,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":48,"overallStatus":57,"whyStopped":48,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Celltrion","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"CT-P53","EXPERIMENTAL","CT-P53(Ocrelizumab)",[13],"Biological: CT-P53",{"label":15,"type":16,"description":17,"interventionNames":18},"US-Ocrevus","ACTIVE_COMPARATOR","US-licensed Ocrevus(Ocrelizumab)",[19],"Biological: US-Ocrevus",{"label":21,"type":16,"description":22,"interventionNames":23},"EU-Ocrevus","EU-approved Ocrevus(Ocrelizumab)",[24],"Biological: EU-Ocrevus",[26,32,35],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"BIOLOGICAL","Intravenous(IV) infusion",[9],[31],"Ocrelizumab",{"type":27,"name":15,"description":28,"armGroupLabels":33,"otherNames":34},[15],[31],{"type":27,"name":21,"description":28,"armGroupLabels":36,"otherNames":37},[21],[31],[39],{"name":40,"affiliation":41,"role":42},"Minji Ma","Celltrion, Inc.","STUDY_CHAIR",[44,50],{"name":45,"role":46,"phone":47,"phoneExt":48,"email":49},"SoYoung Yoo","CONTACT","+82 32 850 5791",null,"soyoung.yoo@celltrion.com",{"name":51,"role":46,"phone":52,"phoneExt":48,"email":53},"JinHo Lee","+82 32 850 5787","jinho.lee2@celltrion.com",[55],{"facility":56,"status":57,"city":58,"state":48,"zip":48,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":48},"CT-P53 3.1 investigational site","RECRUITING","Poznan","Poland","PL",{"type":62,"coordinates":63},"Point",[64,65],16.92993,52.40692,{"lat":65,"lon":64},{"type":68,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR","100508943","phase-3-a-study-to-compare-efficacy-pharmacokinetics-pharmacodynamics-and-safety-of-ct-p53-and-ocrevus-in-patients-with-relapsing-remitting-multiple-sclerosis-100508943",false,"NCT05906992","A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 1\u002F3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","Inclusion Criteria:\n\n* Patient diagnosed as multiple sclerosis (MS) in accordance with the revised McDonald criteria.\n* Patient has evidence of recent MS activity as defined in the study protocol\n* Patient has neurological stability for ≥30 days.\n* Patient with 0 to 6.0 (both inclusive) on the EDSS score.\n\nExclusion Criteria:\n\n* Patient diagnosed with primary or secondary progressive MS.\n* Patient diagnosed with MS for more than 15 years duration with an EDSS score ≤2.0 at Screening.\n* Patient unable to complete or has a contraindication to an MRI\n* Patient with contraindications and\u002For severe hypersensitivity to corticosteroids including methylprednisolone or any of the excipients of study drug or etcs defined in the study protocol.\n* Patient who has currently or history of any of medical conditions described in the study protocol.\n* Patients who have received or going to receive any of prohibited medications or treatments defined in the study protocol.","ALL","18 Years","55 Years",{"count":80,"type":81},512,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","This is a double-blind, randomized, active-controlled, parallel group, Phase 1\u002F3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.",[87],"Relapsing-remitting Multiple Sclerosis","2024-05-20",{"date":90,"type":91},"2024-05-22","ACTUAL",{"date":93,"type":91},"2024-01-11",{"date":95,"type":81},"2029-01",{"name":5,"class":6},1]